Cancer Immunotherapy
-
Cancer Immunotherapy: Chapter 3. Adaptive Immunity: B Cells and Antibodies
By Lauren M.F. Merlo, Laura Mandik-NayakQi H, Egen JG, Huang AYC, Germain RN. Extrafollicular activation of lymph node B cells by antigenbearing dendritic cells. Science. 2006;312:1672–1676. Huang NN, Han SB, Hwang IY, Kehrl JH. B cells productively engage soluble ...
-
Cancer Immunotherapy: Chapter 24. Immune Stimulatory Features of Classical Chemotherapy
By W. Joost Lesterhuis, Anna K. Nowak, Richard A. LakeNowak AK, Robinson BW, Lake RA. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res. 2003;63(15):4490–4496. Nowak AK, Robinson BW, Lake RA. Gemcitabine exerts a selective effect ...
-
Cancer Immunotherapy
By James Allison, Glen DranoffSuganuma, M., Okabe, S., Marino, M. W., Sakai, A., ... Terabe, M., Matsui, S., Park, J. M., Mamura, M., Noben‐Trauth, N., Donaldson, D. D., Chen, W., Wahl, S. M., Ledbetter, S., Pratt, B., Letterio, J. J., Paul, W. E., et al. (2003).
-
Cancer Immunotherapy: Chapter 14. Monoclonal Antibodies for Cancer Therapy and Prevention: Paradigm Studies in Targeting the neu/ERBB2/HER2 Oncoprotein
By Hongtao Zhang, Arabinda Samanta, Yasuhiro NagaiAcademic Press is an imprint of Elsevier 525 B Street, Suite 1900, San Diego, CA 921014495, USA 32 Jamestown Road, London NW17BY, UK 225 Wyman Street, Waltham, MA 02451, USA First edition 2007 Copyright © 2013 Elsevier Inc. All rights ...
-
Cancer Immunotherapy: Chapter 32. IDO in Immune Escape: Regulation and Therapeutic Inhibition
By Courtney Smith, Alexander J. Muller, Richard MetzIndoleamine 2,3-dioxygenase (IDO) is an enzyme that degrades the essential amino acid tryptophan independent of the process that maintains normal tryptophan homeostasis.
-
Cancer Immunotherapy: Chapter 26. JAK/STAT Signaling in Myeloid Cells: Targets for Cancer Immunotherapy
By Saul J. Priceman, Jiehui Deng, Richard JoveGordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions. Immunity. 2010 May 28;32(5):593–604. Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest.
-
Cancer Immunotherapy: Chapter 19. Antibodies to Stimulate Host Immunity: Lessons from Ipilimumab
By Margaret K. Callahan, Michael A. Postow, Jedd D. WolchokBlansfield JA, Beck KE, Tran K, et al. Cytotoxic Tlymphocyteassociated antigen4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother. 2005;28(6):593–598. Ku GY, Yuan J, Page DB, ...
-
Cancer Immunotherapy: Chapter 15. Genetic Vaccines against Cancer: Design, Testing and Clinical Performance
By Freda K. Stevenson, Gianfranco di Genova, Christian H. OttensmeierJanssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, Schoenberger SP. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature. 2003;421(6925):852–856. Timmerman JM, Levy R. Linkage of foreign ...
-
Cancer Immunotherapy: Chapter 29. HyperAcute Vaccines: A Novel Cancer Immunotherapy
By Gabriela R. Rossi, Nicholas N. Vahanian, W. Jay RamseyLarsen RD, RiveraMarrero CA, Ernst LK, Cummings RD, Lowe JB. Frameshift and nonsense mutations in a human genomic sequence homologous to a murine UDPGal:betaDGal(1,4)DGlcNAc alpha(1,3)galactosyltransferase cDNA. J Biol Chem.
-
Cancer Immunotherapy: Chapter 33. IDO Pathway: Effect on Foxp3+ Tregs and Cancer
By David H. Munn, Andrew L. MellorProcaccini C, Galgani M, De Rosa V, Matarese G. Intracellular metabolic pathways control immune tolerance. Trends Immunol. ... Singh NP, Singh UP, Singh B, Price RL, Nagarkatti M, Nagarkatti PS. ... Brenk M, Scheler M, Koch S, et al.
-
Cancer Immunotherapy: Chapter 10. Th17 Cells in Cancer
By Ende Zhao, Lin Wang, Shuang WeiZhou L, Lopes JE, Chong MM, et al. TGFbetainduced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature. 2008;453(7192):236–240. Cosmi L, Maggi L, Santarlasci V, et al. Identification of a novel subset of ...
-
Cancer Immunotherapy: Immune Suppression and Tumor Growth
By George C. Prendergast, Elizabeth M. JaffeeThis book provides basic, translational, and clinical cancer researchers an indispensable overview of immune escape as a critical trait in cancer and how applying specific combinations of immunotherapy and chemotherapy to attack this trait ...
-
Cancer Immunotherapy
By David B. TeplowCancer Immunotherapy, Volume 165 in the Progress in Molecular Biology and Translational Science series, provides informative monographs on a variety of research topics related to different approaches to cancer immunotherapy, with this ...
-
Cancer Immunotherapy: Chapter 1. Introduction
By George C. Prendergast, Elizabeth M. JaffeeThis book introduces new concepts and practices that will dramatically affect oncology by adding new immune modalities to present standards of care in surgery, radiotherapy and chemotherapy.
-
Cancer Immunotherapy: Chapter 20. Recombinant TRICOM-based Therapeutic Cancer Vaccines: Lessons Learned
By James L. Gulley, James W. Hodge, Jeffrey SchlomThis article reviews progress made in the design and development of recombinant poxviral-based vaccines that express transgenes for tumor-associated antigens (TAAs) and human T-cell co-stimulatory molecules (designated TRICOM).
-
Cancer Immunotherapy: Chapter 25. Immunotherapy and Cancer Therapeutics: A Rich Partnership
By Gang Chen, Elizabeth M. Jaffee, Leisha A. EmensCancer is managed by surgery, radiation therapy, and systemic drug therapies.
-
Cancer Immunotherapy: Chapter 31. Galectins: Key Players in the Tumor Microenvironment
By Robert Kiss, Victoria Sundblad, Veronique MathieuGalectins: Key Players in the Tumor Microenvironment Victoria Sundblad, Veronique Mathieu, Robert Kiss, ... premise that tumors may subvert tumor immunity by promoting the expansion, recruitment and activation of Treg cells [102,103].
-
Cancer Immunotherapy: Immune Suppression and Tumor Growth
By George C. Prendergast, Elizabeth M. JaffeeThis book provides basic, translational, and clinical cancer researchers with an indispensable overview of immune escape as a critical trait in cancer and how applying specific combinations of immunotherapy and chemotherapy to attack this ...
-
Cancer Immunotherapy: Chapter 18. Dendritic Cell Vaccines: Sipuleucel-T and Other Approaches
By Charles G. Drake, Nicholas M. DurhamThe idea of a preventive vaccine against cancer has been extremely attractive because of the immune system’s ability to develop specific and long-lasting immunological memory.
-
Cancer Immunotherapy: Chapter 21. Adjuvant Strategies for Vaccines: The Use of Adjuvants within the Cancer Vaccine Setting
By Claire Hearnden, Ed C. LavelleThis chapter describes the types of adjuvants that are being investigated as potential cancer adjuvant candidates and those that are currently being used in vaccines against certain cancers.